#1 / 9546 Total
Type:
Candle Line OHLC Hollow Candle Heikin Ashi
TA: on | off
Refresh: 3min | off
Page 1 / 955 Page 2 / 955 Page 3 / 955 Page 4 / 955 Page 5 / 955 Page 6 / 955 Page 7 / 955 Page 8 / 955 Page 9 / 955 Page 10 / 955 Page 11 / 955 Page 12 / 955 Page 13 / 955 Page 14 / 955 Page 15 / 955 Page 16 / 955 Page 17 / 955 Page 18 / 955 Page 19 / 955 Page 20 / 955 Page 21 / 955 Page 22 / 955 Page 23 / 955 Page 24 / 955 Page 25 / 955 Page 26 / 955 Page 27 / 955 Page 28 / 955 Page 29 / 955 Page 30 / 955 Page 31 / 955 Page 32 / 955 Page 33 / 955 Page 34 / 955 Page 35 / 955 Page 36 / 955 Page 37 / 955 Page 38 / 955 Page 39 / 955 Page 40 / 955 Page 41 / 955 Page 42 / 955 Page 43 / 955 Page 44 / 955 Page 45 / 955 Page 46 / 955 Page 47 / 955 Page 48 / 955 Page 49 / 955 Page 50 / 955 Page 51 / 955 Page 52 / 955 Page 53 / 955 Page 54 / 955 Page 55 / 955 Page 56 / 955 Page 57 / 955 Page 58 / 955 Page 59 / 955 Page 60 / 955 Page 61 / 955 Page 62 / 955 Page 63 / 955 Page 64 / 955 Page 65 / 955 Page 66 / 955 Page 67 / 955 Page 68 / 955 Page 69 / 955 Page 70 / 955 Page 71 / 955 Page 72 / 955 Page 73 / 955 Page 74 / 955 Page 75 / 955 Page 76 / 955 Page 77 / 955 Page 78 / 955 Page 79 / 955 Page 80 / 955 Page 81 / 955 Page 82 / 955 Page 83 / 955 Page 84 / 955 Page 85 / 955 Page 86 / 955 Page 87 / 955 Page 88 / 955 Page 89 / 955 Page 90 / 955 Page 91 / 955 Page 92 / 955 Page 93 / 955 Page 94 / 955 Page 95 / 955 Page 96 / 955 Page 97 / 955 Page 98 / 955 Page 99 / 955 Page 100 / 955 Page 101 / 955 Page 102 / 955 Page 103 / 955 Page 104 / 955 Page 105 / 955 Page 106 / 955 Page 107 / 955 Page 108 / 955 Page 109 / 955 Page 110 / 955 Page 111 / 955 Page 112 / 955 Page 113 / 955 Page 114 / 955 Page 115 / 955 Page 116 / 955 Page 117 / 955 Page 118 / 955 Page 119 / 955 Page 120 / 955 Page 121 / 955 Page 122 / 955 Page 123 / 955 Page 124 / 955 Page 125 / 955 Page 126 / 955 Page 127 / 955 Page 128 / 955 Page 129 / 955 Page 130 / 955 Page 131 / 955 Page 132 / 955 Page 133 / 955 Page 134 / 955 Page 135 / 955 Page 136 / 955 Page 137 / 955 Page 138 / 955 Page 139 / 955 Page 140 / 955 Page 141 / 955 Page 142 / 955 Page 143 / 955 Page 144 / 955 Page 145 / 955 Page 146 / 955 Page 147 / 955 Page 148 / 955 Page 149 / 955 Page 150 / 955 Page 151 / 955 Page 152 / 955 Page 153 / 955 Page 154 / 955 Page 155 / 955 Page 156 / 955 Page 157 / 955 Page 158 / 955 Page 159 / 955 Page 160 / 955 Page 161 / 955 Page 162 / 955 Page 163 / 955 Page 164 / 955 Page 165 / 955 Page 166 / 955 Page 167 / 955 Page 168 / 955 Page 169 / 955 Page 170 / 955 Page 171 / 955 Page 172 / 955 Page 173 / 955 Page 174 / 955 Page 175 / 955 Page 176 / 955 Page 177 / 955 Page 178 / 955 Page 179 / 955 Page 180 / 955 Page 181 / 955 Page 182 / 955 Page 183 / 955 Page 184 / 955 Page 185 / 955 Page 186 / 955 Page 187 / 955 Page 188 / 955 Page 189 / 955 Page 190 / 955 Page 191 / 955 Page 192 / 955 Page 193 / 955 Page 194 / 955 Page 195 / 955 Page 196 / 955 Page 197 / 955 Page 198 / 955 Page 199 / 955 Page 200 / 955 Page 201 / 955 Page 202 / 955 Page 203 / 955 Page 204 / 955 Page 205 / 955 Page 206 / 955 Page 207 / 955 Page 208 / 955 Page 209 / 955 Page 210 / 955 Page 211 / 955 Page 212 / 955 Page 213 / 955 Page 214 / 955 Page 215 / 955 Page 216 / 955 Page 217 / 955 Page 218 / 955 Page 219 / 955 Page 220 / 955 Page 221 / 955 Page 222 / 955 Page 223 / 955 Page 224 / 955 Page 225 / 955 Page 226 / 955 Page 227 / 955 Page 228 / 955 Page 229 / 955 Page 230 / 955 Page 231 / 955 Page 232 / 955 Page 233 / 955 Page 234 / 955 Page 235 / 955 Page 236 / 955 Page 237 / 955 Page 238 / 955 Page 239 / 955 Page 240 / 955 Page 241 / 955 Page 242 / 955 Page 243 / 955 Page 244 / 955 Page 245 / 955 Page 246 / 955 Page 247 / 955 Page 248 / 955 Page 249 / 955 Page 250 / 955 Page 251 / 955 Page 252 / 955 Page 253 / 955 Page 254 / 955 Page 255 / 955 Page 256 / 955 Page 257 / 955 Page 258 / 955 Page 259 / 955 Page 260 / 955 Page 261 / 955 Page 262 / 955 Page 263 / 955 Page 264 / 955 Page 265 / 955 Page 266 / 955 Page 267 / 955 Page 268 / 955 Page 269 / 955 Page 270 / 955 Page 271 / 955 Page 272 / 955 Page 273 / 955 Page 274 / 955 Page 275 / 955 Page 276 / 955 Page 277 / 955 Page 278 / 955 Page 279 / 955 Page 280 / 955 Page 281 / 955 Page 282 / 955 Page 283 / 955 Page 284 / 955 Page 285 / 955 Page 286 / 955 Page 287 / 955 Page 288 / 955 Page 289 / 955 Page 290 / 955 Page 291 / 955 Page 292 / 955 Page 293 / 955 Page 294 / 955 Page 295 / 955 Page 296 / 955 Page 297 / 955 Page 298 / 955 Page 299 / 955 Page 300 / 955 Page 301 / 955 Page 302 / 955 Page 303 / 955 Page 304 / 955 Page 305 / 955 Page 306 / 955 Page 307 / 955 Page 308 / 955 Page 309 / 955 Page 310 / 955 Page 311 / 955 Page 312 / 955 Page 313 / 955 Page 314 / 955 Page 315 / 955 Page 316 / 955 Page 317 / 955 Page 318 / 955 Page 319 / 955 Page 320 / 955 Page 321 / 955 Page 322 / 955 Page 323 / 955 Page 324 / 955 Page 325 / 955 Page 326 / 955 Page 327 / 955 Page 328 / 955 Page 329 / 955 Page 330 / 955 Page 331 / 955 Page 332 / 955 Page 333 / 955 Page 334 / 955 Page 335 / 955 Page 336 / 955 Page 337 / 955 Page 338 / 955 Page 339 / 955 Page 340 / 955 Page 341 / 955 Page 342 / 955 Page 343 / 955 Page 344 / 955 Page 345 / 955 Page 346 / 955 Page 347 / 955 Page 348 / 955 Page 349 / 955 Page 350 / 955 Page 351 / 955 Page 352 / 955 Page 353 / 955 Page 354 / 955 Page 355 / 955 Page 356 / 955 Page 357 / 955 Page 358 / 955 Page 359 / 955 Page 360 / 955 Page 361 / 955 Page 362 / 955 Page 363 / 955 Page 364 / 955 Page 365 / 955 Page 366 / 955 Page 367 / 955 Page 368 / 955 Page 369 / 955 Page 370 / 955 Page 371 / 955 Page 372 / 955 Page 373 / 955 Page 374 / 955 Page 375 / 955 Page 376 / 955 Page 377 / 955 Page 378 / 955 Page 379 / 955 Page 380 / 955 Page 381 / 955 Page 382 / 955 Page 383 / 955 Page 384 / 955 Page 385 / 955 Page 386 / 955 Page 387 / 955 Page 388 / 955 Page 389 / 955 Page 390 / 955 Page 391 / 955 Page 392 / 955 Page 393 / 955 Page 394 / 955 Page 395 / 955 Page 396 / 955 Page 397 / 955 Page 398 / 955 Page 399 / 955 Page 400 / 955 Page 401 / 955 Page 402 / 955 Page 403 / 955 Page 404 / 955 Page 405 / 955 Page 406 / 955 Page 407 / 955 Page 408 / 955 Page 409 / 955 Page 410 / 955 Page 411 / 955 Page 412 / 955 Page 413 / 955 Page 414 / 955 Page 415 / 955 Page 416 / 955 Page 417 / 955 Page 418 / 955 Page 419 / 955 Page 420 / 955 Page 421 / 955 Page 422 / 955 Page 423 / 955 Page 424 / 955 Page 425 / 955 Page 426 / 955 Page 427 / 955 Page 428 / 955 Page 429 / 955 Page 430 / 955 Page 431 / 955 Page 432 / 955 Page 433 / 955 Page 434 / 955 Page 435 / 955 Page 436 / 955 Page 437 / 955 Page 438 / 955 Page 439 / 955 Page 440 / 955 Page 441 / 955 Page 442 / 955 Page 443 / 955 Page 444 / 955 Page 445 / 955 Page 446 / 955 Page 447 / 955 Page 448 / 955 Page 449 / 955 Page 450 / 955 Page 451 / 955 Page 452 / 955 Page 453 / 955 Page 454 / 955 Page 455 / 955 Page 456 / 955 Page 457 / 955 Page 458 / 955 Page 459 / 955 Page 460 / 955 Page 461 / 955 Page 462 / 955 Page 463 / 955 Page 464 / 955 Page 465 / 955 Page 466 / 955 Page 467 / 955 Page 468 / 955 Page 469 / 955 Page 470 / 955 Page 471 / 955 Page 472 / 955 Page 473 / 955 Page 474 / 955 Page 475 / 955 Page 476 / 955 Page 477 / 955 Page 478 / 955 Page 479 / 955 Page 480 / 955 Page 481 / 955 Page 482 / 955 Page 483 / 955 Page 484 / 955 Page 485 / 955 Page 486 / 955 Page 487 / 955 Page 488 / 955 Page 489 / 955 Page 490 / 955 Page 491 / 955 Page 492 / 955 Page 493 / 955 Page 494 / 955 Page 495 / 955 Page 496 / 955 Page 497 / 955 Page 498 / 955 Page 499 / 955 Page 500 / 955 Page 501 / 955 Page 502 / 955 Page 503 / 955 Page 504 / 955 Page 505 / 955 Page 506 / 955 Page 507 / 955 Page 508 / 955 Page 509 / 955 Page 510 / 955 Page 511 / 955 Page 512 / 955 Page 513 / 955 Page 514 / 955 Page 515 / 955 Page 516 / 955 Page 517 / 955 Page 518 / 955 Page 519 / 955 Page 520 / 955 Page 521 / 955 Page 522 / 955 Page 523 / 955 Page 524 / 955 Page 525 / 955 Page 526 / 955 Page 527 / 955 Page 528 / 955 Page 529 / 955 Page 530 / 955 Page 531 / 955 Page 532 / 955 Page 533 / 955 Page 534 / 955 Page 535 / 955 Page 536 / 955 Page 537 / 955 Page 538 / 955 Page 539 / 955 Page 540 / 955 Page 541 / 955 Page 542 / 955 Page 543 / 955 Page 544 / 955 Page 545 / 955 Page 546 / 955 Page 547 / 955 Page 548 / 955 Page 549 / 955 Page 550 / 955 Page 551 / 955 Page 552 / 955 Page 553 / 955 Page 554 / 955 Page 555 / 955 Page 556 / 955 Page 557 / 955 Page 558 / 955 Page 559 / 955 Page 560 / 955 Page 561 / 955 Page 562 / 955 Page 563 / 955 Page 564 / 955 Page 565 / 955 Page 566 / 955 Page 567 / 955 Page 568 / 955 Page 569 / 955 Page 570 / 955 Page 571 / 955 Page 572 / 955 Page 573 / 955 Page 574 / 955 Page 575 / 955 Page 576 / 955 Page 577 / 955 Page 578 / 955 Page 579 / 955 Page 580 / 955 Page 581 / 955 Page 582 / 955 Page 583 / 955 Page 584 / 955 Page 585 / 955 Page 586 / 955 Page 587 / 955 Page 588 / 955 Page 589 / 955 Page 590 / 955 Page 591 / 955 Page 592 / 955 Page 593 / 955 Page 594 / 955 Page 595 / 955 Page 596 / 955 Page 597 / 955 Page 598 / 955 Page 599 / 955 Page 600 / 955 Page 601 / 955 Page 602 / 955 Page 603 / 955 Page 604 / 955 Page 605 / 955 Page 606 / 955 Page 607 / 955 Page 608 / 955 Page 609 / 955 Page 610 / 955 Page 611 / 955 Page 612 / 955 Page 613 / 955 Page 614 / 955 Page 615 / 955 Page 616 / 955 Page 617 / 955 Page 618 / 955 Page 619 / 955 Page 620 / 955 Page 621 / 955 Page 622 / 955 Page 623 / 955 Page 624 / 955 Page 625 / 955 Page 626 / 955 Page 627 / 955 Page 628 / 955 Page 629 / 955 Page 630 / 955 Page 631 / 955 Page 632 / 955 Page 633 / 955 Page 634 / 955 Page 635 / 955 Page 636 / 955 Page 637 / 955 Page 638 / 955 Page 639 / 955 Page 640 / 955 Page 641 / 955 Page 642 / 955 Page 643 / 955 Page 644 / 955 Page 645 / 955 Page 646 / 955 Page 647 / 955 Page 648 / 955 Page 649 / 955 Page 650 / 955 Page 651 / 955 Page 652 / 955 Page 653 / 955 Page 654 / 955 Page 655 / 955 Page 656 / 955 Page 657 / 955 Page 658 / 955 Page 659 / 955 Page 660 / 955 Page 661 / 955 Page 662 / 955 Page 663 / 955 Page 664 / 955 Page 665 / 955 Page 666 / 955 Page 667 / 955 Page 668 / 955 Page 669 / 955 Page 670 / 955 Page 671 / 955 Page 672 / 955 Page 673 / 955 Page 674 / 955 Page 675 / 955 Page 676 / 955 Page 677 / 955 Page 678 / 955 Page 679 / 955 Page 680 / 955 Page 681 / 955 Page 682 / 955 Page 683 / 955 Page 684 / 955 Page 685 / 955 Page 686 / 955 Page 687 / 955 Page 688 / 955 Page 689 / 955 Page 690 / 955 Page 691 / 955 Page 692 / 955 Page 693 / 955 Page 694 / 955 Page 695 / 955 Page 696 / 955 Page 697 / 955 Page 698 / 955 Page 699 / 955 Page 700 / 955 Page 701 / 955 Page 702 / 955 Page 703 / 955 Page 704 / 955 Page 705 / 955 Page 706 / 955 Page 707 / 955 Page 708 / 955 Page 709 / 955 Page 710 / 955 Page 711 / 955 Page 712 / 955 Page 713 / 955 Page 714 / 955 Page 715 / 955 Page 716 / 955 Page 717 / 955 Page 718 / 955 Page 719 / 955 Page 720 / 955 Page 721 / 955 Page 722 / 955 Page 723 / 955 Page 724 / 955 Page 725 / 955 Page 726 / 955 Page 727 / 955 Page 728 / 955 Page 729 / 955 Page 730 / 955 Page 731 / 955 Page 732 / 955 Page 733 / 955 Page 734 / 955 Page 735 / 955 Page 736 / 955 Page 737 / 955 Page 738 / 955 Page 739 / 955 Page 740 / 955 Page 741 / 955 Page 742 / 955 Page 743 / 955 Page 744 / 955 Page 745 / 955 Page 746 / 955 Page 747 / 955 Page 748 / 955 Page 749 / 955 Page 750 / 955 Page 751 / 955 Page 752 / 955 Page 753 / 955 Page 754 / 955 Page 755 / 955 Page 756 / 955 Page 757 / 955 Page 758 / 955 Page 759 / 955 Page 760 / 955 Page 761 / 955 Page 762 / 955 Page 763 / 955 Page 764 / 955 Page 765 / 955 Page 766 / 955 Page 767 / 955 Page 768 / 955 Page 769 / 955 Page 770 / 955 Page 771 / 955 Page 772 / 955 Page 773 / 955 Page 774 / 955 Page 775 / 955 Page 776 / 955 Page 777 / 955 Page 778 / 955 Page 779 / 955 Page 780 / 955 Page 781 / 955 Page 782 / 955 Page 783 / 955 Page 784 / 955 Page 785 / 955 Page 786 / 955 Page 787 / 955 Page 788 / 955 Page 789 / 955 Page 790 / 955 Page 791 / 955 Page 792 / 955 Page 793 / 955 Page 794 / 955 Page 795 / 955 Page 796 / 955 Page 797 / 955 Page 798 / 955 Page 799 / 955 Page 800 / 955 Page 801 / 955 Page 802 / 955 Page 803 / 955 Page 804 / 955 Page 805 / 955 Page 806 / 955 Page 807 / 955 Page 808 / 955 Page 809 / 955 Page 810 / 955 Page 811 / 955 Page 812 / 955 Page 813 / 955 Page 814 / 955 Page 815 / 955 Page 816 / 955 Page 817 / 955 Page 818 / 955 Page 819 / 955 Page 820 / 955 Page 821 / 955 Page 822 / 955 Page 823 / 955 Page 824 / 955 Page 825 / 955 Page 826 / 955 Page 827 / 955 Page 828 / 955 Page 829 / 955 Page 830 / 955 Page 831 / 955 Page 832 / 955 Page 833 / 955 Page 834 / 955 Page 835 / 955 Page 836 / 955 Page 837 / 955 Page 838 / 955 Page 839 / 955 Page 840 / 955 Page 841 / 955 Page 842 / 955 Page 843 / 955 Page 844 / 955 Page 845 / 955 Page 846 / 955 Page 847 / 955 Page 848 / 955 Page 849 / 955 Page 850 / 955 Page 851 / 955 Page 852 / 955 Page 853 / 955 Page 854 / 955 Page 855 / 955 Page 856 / 955 Page 857 / 955 Page 858 / 955 Page 859 / 955 Page 860 / 955 Page 861 / 955 Page 862 / 955 Page 863 / 955 Page 864 / 955 Page 865 / 955 Page 866 / 955 Page 867 / 955 Page 868 / 955 Page 869 / 955 Page 870 / 955 Page 871 / 955 Page 872 / 955 Page 873 / 955 Page 874 / 955 Page 875 / 955 Page 876 / 955 Page 877 / 955 Page 878 / 955 Page 879 / 955 Page 880 / 955 Page 881 / 955 Page 882 / 955 Page 883 / 955 Page 884 / 955 Page 885 / 955 Page 886 / 955 Page 887 / 955 Page 888 / 955 Page 889 / 955 Page 890 / 955 Page 891 / 955 Page 892 / 955 Page 893 / 955 Page 894 / 955 Page 895 / 955 Page 896 / 955 Page 897 / 955 Page 898 / 955 Page 899 / 955 Page 900 / 955 Page 901 / 955 Page 902 / 955 Page 903 / 955 Page 904 / 955 Page 905 / 955 Page 906 / 955 Page 907 / 955 Page 908 / 955 Page 909 / 955 Page 910 / 955 Page 911 / 955 Page 912 / 955 Page 913 / 955 Page 914 / 955 Page 915 / 955 Page 916 / 955 Page 917 / 955 Page 918 / 955 Page 919 / 955 Page 920 / 955 Page 921 / 955 Page 922 / 955 Page 923 / 955 Page 924 / 955 Page 925 / 955 Page 926 / 955 Page 927 / 955 Page 928 / 955 Page 929 / 955 Page 930 / 955 Page 931 / 955 Page 932 / 955 Page 933 / 955 Page 934 / 955 Page 935 / 955 Page 936 / 955 Page 937 / 955 Page 938 / 955 Page 939 / 955 Page 940 / 955 Page 941 / 955 Page 942 / 955 Page 943 / 955 Page 944 / 955 Page 945 / 955 Page 946 / 955 Page 947 / 955 Page 948 / 955 Page 949 / 955 Page 950 / 955 Page 951 / 955 Page 952 / 955 Page 953 / 955 Page 954 / 955 Page 955 / 955
Market Cap 39.36B EPS (ttm) 4.23
P/E 31.87 EPS this Y -4.34%
Forward P/E 23.59 EPS next Y 9.90%
PEG 6.44 EPS past 5Y 33.93%
P/S 5.97 EPS next 5Y 4.95%
P/B 6.33 EPS Q/Q 3.38%
Dividend 0.70% Sales Q/Q -8.39%
Insider Own 0.42% Inst Own 92.37%
Insider Trans -8.19% Inst Trans -3.30%
Short Float 1.52% Earnings May 29/a
Analyst Recom 2.52 Target Price 138.10
Avg Volume 1.67M 52W Range 96.80 - 155.35
Jun-14-24 06:54AM
Agilent to cut 3% of employees as sluggish lab equipment market persists
(MedTech Dive)
Jun-06-24 12:01PM
Agilent (A) Boosts Reach to Lab Researchers With New Devices
(Zacks)
Jun-03-24 11:27AM
Investing in Agilent (A)? Don't Miss Assessing Its International Revenue Trends
(Zacks)
11:00AM
Agilent Announces Cutting-Edge Advances in GC/MS and LC/Q-TOF Technology at ASMS 2024
(Business Wire)
May-31-24 07:34PM
Analyst Report: Agilent Technologies, Inc.
(Morningstar Research)
May-30-24 04:24PM
These Stocks Moved the Most Today: Salesforce, UiPath, HP Inc., Best Buy, Kohls, Foot Locker, C3.ai, Nutanix, and More
(Barrons.com) -9.66%
02:36PM
These Stocks Are Moving the Most Today: Salesforce, UiPath, HP Inc., Best Buy, Kohls, Foot Locker, C3.ai, Nutanix, and More
(Barrons.com)
12:15PM
Salesforce, Agilent fall; HP, Foot Locker rise, Thursday, 5/30/2024
(Associated Press Finance)
11:58AM
Agilent (A) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
(Zacks)
11:34AM
Analyst Report: Agilent Technologies, Inc.
(Morningstar Research)
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Grau Dominique Senior Vice President Jun 10 '24 Sale 133.28 15,000 1,999,262 49,486 Jun 12 10:40 AM MCDONNELL PADRAIG President and CEO Jun 03 '24 Sale 130.00 1,958 254,540 25,185 Jun 05 10:08 AM Binns Philip Senior Vice President Mar 25 '24 Sale 147.54 2,827 417,096 9,997 Mar 27 01:29 PM McMullen Michael R. CEO and President Mar 08 '24 Sale 150.00 52,297 7,844,550 253,909 Mar 12 02:37 PM Gonsalves Rodney V.P., Corporate Controller Mar 07 '24 Sale 149.00 4,828 719,348 21,329 Mar 08 12:05 PM
Market Cap 6.73B EPS (ttm) -3.77
P/E - EPS this Y 101.05%
Forward P/E 16.61 EPS next Y 9330.90%
PEG - EPS past 5Y -
P/S 0.63 EPS next 5Y 63.40%
P/B 1.69 EPS Q/Q -8.48%
Dividend 0.93% Sales Q/Q -3.07%
Insider Own 1.13% Inst Own 85.04%
Insider Trans -1.36% Inst Trans -5.63%
Short Float 7.04% Earnings Apr 17/a
Analyst Recom 3.07 Target Price 38.15
Avg Volume 5.90M 52W Range 23.07 - 45.48
Alcoa Corp. engages in the production of bauxite, alumina, and aluminum products. Its Products include ecolum, ecosource & ecodura. The company operates through the following segments: Bauxite, Alumina, and Aluminum. The Bauxite segment represents the company' global bauxite mining operations. The Alumina segment includes the company's worldwide refining system, which processes bauxite into alumina. The Aluminum segment combines smelting and casting operations to produce primary aluminum. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jones Tammi A EVP & CHRO Mar 13 '24 Sale 30.78 26,468 814,582 41,166 Mar 15 04:09 PM Jones Tammi A EVP & CHRO Mar 13 '24 Sale 30.67 1,440 44,165 9,265 Mar 15 04:09 PM
Category Bonds - Non Government Asset Backed Securities
Index -
Tags U.S. , debt , debt-securities , CLO
Sector/Theme
Region
Dividend 6.26% Active/Passive
Total Holdings 48 AUM 22.55M
Flows% 1M 0.00% Flows% 3M 28.48%
Flows% YTD 79.63% Flows% 1Y
Return% 1Y 8.73% Return% 3Y 0.04%
Return% 5Y - Return% 10Y
NAV%
Expense
Avg Volume 8.17K 52W Range 24.12 - 25.26
AXS First Priority CLO Bond ETF seeks capital preservation and income. The fund is an actively-managed exchange-traded fund ("ETF"). Under normal circumstances, it invests at least 80% of its net assets (plus any borrowings for investment purposes) in AAA rated first priority debt tranches of U.S. dollar-dominated collateralized loan obligations ("CLOs"). It may invest in CLOs of any maturity. The fund is actively managed and does not seek to track the performance of any particular index.
Category Commodities & Metals - Gold / Metals
Index Gold - London PM Gold Price
Tags Global , commodity , gold , physical
Sector/Theme
Region
Dividend - Active/Passive
Total Holdings 1 AUM 712.94M
Flows% 1M 3.02% Flows% 3M 7.34%
Flows% YTD 2.12% Flows% 1Y
Return% 1Y 18.18% Return% 3Y 0.07%
Return% 5Y 11.38% Return% 10Y
NAV%
Expense
Avg Volume 3.00M 52W Range 17.97 - 24.12
Goldman Sachs Physical Gold ETF seeks to provide investors with an opportunity to invest in gold through shares, and have the gold securely stored by the Custodial Sponsor; reflecting the performance of the price of gold less the expenses of the trust's operations is the secondary consideration. The trust holds London Bars and Physical Gold of other specifications without numismatic value. It receives gold deposited by Authorized Participants in exchange for the creation of Baskets and delivers gold to Authorized Participants in exchange for Baskets surrendered to it for redemption.
Market Cap 26.45M EPS (ttm) -0.15
P/E - EPS this Y -
Forward P/E - EPS next Y -
PEG - EPS past 5Y 25.83%
P/S 0.84 EPS next 5Y 25.00%
P/B 1.66 EPS Q/Q 3.87%
Dividend - Sales Q/Q 8.25%
Insider Own - Inst Own 16.58%
Insider Trans - Inst Trans -0.76%
Short Float 0.16% Earnings May 14/a
Analyst Recom 1.00 Target Price 6.50
Avg Volume 23.07K 52W Range 0.78 - 1.65
ATA Creativity Global engages in the provision of quality learning experiences that cultivate and enhance students' creativity. It offers a range of education services consisting primarily of portfolio training, research-based learning, overseas study counselling and other educational services through its training center network. It operates under the following segments: Overseas Art Study Services, Other Educational Services, and K-12 Education Assessment and Other Services. The company was founded by Kevin Xiaofeng Ma and Walter Lin Wang in 1999 and is headquartered in Beijing, China.
Market Cap 81.85M EPS (ttm) -0.20
P/E - EPS this Y -
Forward P/E - EPS next Y -
PEG - EPS past 5Y -
P/S - EPS next 5Y -
P/B 13.39 EPS Q/Q -1987.50%
Dividend - Sales Q/Q -
Insider Own 77.83% Inst Own 16.58%
Insider Trans 0.00% Inst Trans 23.56%
Short Float 0.02% Earnings -
Analyst Recom - Target Price -
Avg Volume 27.14K 52W Range 10.22 - 12.53
Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.
Market Cap 665.62M EPS (ttm) 0.37
P/E 28.56 EPS this Y -
Forward P/E - EPS next Y -
PEG - EPS past 5Y -
P/S - EPS next 5Y -
P/B 1.31 EPS Q/Q -
Dividend - Sales Q/Q -
Insider Own 20.00% Inst Own 69.65%
Insider Trans 0.00% Inst Trans -
Short Float 0.00% Earnings -
Analyst Recom - Target Price -
Avg Volume 239.40K 52W Range 10.11 - 10.76
Ares Acquisition Corp. II is a blank check company which engages in effecting a merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on March 15, 2021 and is headquartered in New York, NY.
Market Cap 39.53M EPS (ttm) -2.55
P/E - EPS this Y -4.10%
Forward P/E - EPS next Y -12.44%
PEG - EPS past 5Y 11.87%
P/S 1.66 EPS next 5Y -
P/B 0.44 EPS Q/Q -19.60%
Dividend - Sales Q/Q -8.76%
Insider Own 28.99% Inst Own 43.02%
Insider Trans -3.34% Inst Trans 13.61%
Short Float 5.10% Earnings May 08/b
Analyst Recom 1.40 Target Price 11.00
Avg Volume 193.25K 52W Range 1.55 - 8.20
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Desai Neil EXECUTIVE CHAIRMAN Jun 04 '24 Sale 1.77 20,225 35,746 1,291,543 Jun 05 04:25 PM Desai Neil EXECUTIVE CHAIRMAN Jun 03 '24 Sale 1.81 19,775 35,765 1,311,768 Jun 05 04:25 PM Desai Neil EXECUTIVE CHAIRMAN May 01 '24 Sale 1.93 40,000 77,184 1,331,543 May 01 08:50 PM Desai Neil EXECUTIVE CHAIRMAN Apr 02 '24 Sale 2.23 22,228 49,513 1,371,543 Apr 03 04:49 PM Desai Neil EXECUTIVE CHAIRMAN Apr 01 '24 Sale 2.31 17,772 41,101 1,393,771 Apr 03 04:49 PM
Category Global or ExUS Equities - Factor & Thematic
Index -
Tags International , equity
Sector/Theme
Region
Dividend 0.69% Active/Passive
Total Holdings 37 AUM 25.90M
Flows% 1M -2.35% Flows% 3M -6.76%
Flows% YTD -7.77% Flows% 1Y
Return% 1Y 23.84% Return% 3Y -0.03%
Return% 5Y 5.36% Return% 10Y
NAV%
Expense
Avg Volume 1.00K 52W Range 46.37 - 65.40
AdvisorShares Dorsey Wright ADR ETF seeks long-term capital appreciation above international benchmarks such as the MSCI EAFE Index. The fund seeks to achieve the fund's investment objective by selecting primarily a portfolio of U.S.-traded securities of non-U.S. organizations, most often American Depositary Receipts ("ADRs"). It will invest at least 80% of its total assets in ADRs and in securities that have economic characteristics similar to ADRs.
Market Cap 20.78M EPS (ttm) -0.72
P/E - EPS this Y -
Forward P/E - EPS next Y -
PEG - EPS past 5Y -
P/S 16.49 EPS next 5Y -
P/B - EPS Q/Q -24.46%
Dividend - Sales Q/Q -16.93%
Insider Own 72.96% Inst Own 3.84%
Insider Trans 0.00% Inst Trans 2.17%
Short Float 2.51% Earnings -
Analyst Recom - Target Price -
Avg Volume 136.66K 52W Range 0.29 - 11.39
African Agriculture Holdings Inc. engages in the commercial farming business based in northern Senegal focusing on the production and sale of alfalfa for cattle feed and nutrition purposes. The company was founded in February 2021 and is headquartered in New York, NY.
1 2 3 4 5 6 ⋯ 100 ⋯ 200 ⋯ 300 ⋯ 400 ⋯ 500 ⋯ 600 ⋯ 700 ⋯ 800 ⋯ 900 ⋯ 955